Sanofi has entered a research agreement with drug discovery services provider Axxam.

The partnership is aimed at optimising numerous small molecules targeted against a range of diseases of the central nervous system (CNS).

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Axxam expects the partnership to help strengthen its platform to generate leads for discovering small molecule drugs.

Axxam is based in Italy, whereas Sanofi is a pharmaceutical company based in France.

US-based Entasis Therapeutics has completed a series B-1 extension financing round to raise additional $31.9m from Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech.

See Also:

The proceeds are intended to be used to advance the company’s portfolio of anti-infective programmes to mid and late-stage clinical development.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"US-based Entasis Therapeutics has completed a series B-1 extension financing round to raise additional $31.9m from Pivotal bioVenture Partners, Sofinnova Ventures and TPG Biotech."

Helsinn Therapeutics (US) has obtained a non-exclusive, non-sublicensable right from Novartis AG to provide detailing services for the latter’s drug Zykadia in the US, as part of a co-promotion agreement signed between the two companies.

Zykadia is approved as a treatment for patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected with an FDA-approved test.

Novartis is a healthcare company based in Switzerland, while Helsinn Therapeutics is a pharmaceutical company and subsidiary of Helsinn Holding.

India-based pharmaceutical company Sayre Therapeutics Private has closed a second round of venture financing to raise $8m from Accel Partners and Aarin Asset Advisors.

The company has concurrently raised $1m from InnoVen Capital in venture debt financing.

The proceeds will be used to expand the company’s teams in India, perform clinical trials of its in-licensed assets, and to expand its geographical footprint in other South Asian countries.